1974•Antimicrobial Agents and ChemotherapyOpen access

Antimicrobial Susceptibilities of Anaerobic Bacteria: Recent Clinical Isolates

Joseph L. Staneck, John A. Washington

Open full text 61 citations

Abstract

Minimal inhibitory concentrations of clindamycin, minocycline, metronidazole, penicillin, and carbenicillin were determined by agar dilution against 150 recent clinical isolates of anaerobic bacteria. Ninety-nine percent of Bacteroides fragilis and all B. melaninogenicus, Clostridium perfringens, and Fusobacterium were inhibited by clindamycin at 3.1 mug/ml. Only 58% of other clostridial species were inhibited by this concentration of clindamycin. Minocycline at 3.1 mug/ml inhibited 72% of C. perfringens, 81% of other Clostridium species, and 66, 75, and 100% of B. fragilis, B. melaninogenicus, and Fusobacterium, respectively. Metronidazole at 12.5 mug/ml inhibited all bacteria tested. B. fragilis was resistant to both penicillin and carbenicillin at 6.2 mug/ml. Concentrations of 25 mug/ml for penicillin and 100 mug/ml for carbenicillin were needed to inhibit more than 90% of B. fragilis. Organisms other than B. fragilis were moderately or extremely susceptible to the penicillins.

About this research paper

What this paper is about

Minimal inhibitory concentrations of clindamycin, minocycline, metronidazole, penicillin, and carbenicillin were determined by agar dilution against 150 recent clinical isolates of anaerobic bacteria. Ninety-nine percent of Bacteroides fragilis and all B. melaninogenicus, Clostridium perfringens, and Fusobacterium were inhibited by clindamycin at 3.1 mug/ml. Only 58% of other clostridial species were inhibited by this concentration of clindamycin. Minocycline at 3.1 mug/ml inhibited 72% of C. perfringens, 81% of other Clostridium species, and 66, 75, and 100% of B. fragilis, B. melaninogenicus, and Fusobacterium, respectively. Metronidazole at 12.5 mug/ml inhibited all bacteria tested. B. fragilis was resistant to both penicillin and carbenicillin at 6.2 mug/ml. Concentrations of 25 mug/ml for penicillin and 100 mug/ml for carbenicillin were needed to inhibit more than 90% of B. fragilis. Organisms other than B. fragilis were moderately or extremely susceptible to the penicillins.

Why it matters

OpenAlex reports 61 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Minimal inhibitory concentrations of clindamycin, minocycline, metronidazole, penicillin, and carbenicillin were determined by agar dilution against 150 recent clinical isolates of anaerobic bacteria. Ninety-nine percent of Bacteroides fragilis and all B. melaninogenicus, Clostridium perfringens, and Fusobacterium were inhibited by clindamycin at 3.1 mug/ml. Only 58% of other clostridial species were inhibited by this concentration of clindamycin. Minocycline at 3.1 mug/ml inhibited 72% of C. perfringens, 81% of other Clostridium species, and 66, 75, and 100% of B. fragilis, B. melaninogenicus, and Fusobacterium, respectively. Metronidazole at 12.5 mug/ml inhibited all bacteria tested. B. fragilis was resistant to both penicillin and carbenicillin at 6.2 mug/ml. Concentrations of 25 mug/ml for penicillin and 100 mug/ml for carbenicillin were needed to inhibit more than 90% of B. fragilis. Organisms other than B. fragilis were moderately or extremely susceptible to the penicillins.

Key concepts: Bacteroides fragilis, Carbenicillin, Microbiology, Clostridium perfringens, Clindamycin, Penicillin, Anaerobic bacteria, Minocycline

Related papers

Back to paper searchBrowse research topicsOriginal source
Antimicrobial Susceptibilities of Anaerobic Bacteria: Recent Clinical Isolates — Research Paper | ScholarLens